Esperion Therapeutics Inc. (NASDAQ: ESPR) announced a $50 million royalty financing agreement with funds managed by Athyrium Capital Management to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE